Stockscreener 앱 받기
17.03
0.41%
0.07
시간 외 거래:
17.05
0.02
+0.12%
전일 마감가:
$16.96
열려 있는:
$16.9
하루 거래량:
222.82K
Relative Volume:
0.71
시가총액:
$469.60M
수익:
$11.88M
순이익/손실:
$-162.08M
주가수익비율:
-1.3641
EPS:
-12.484
순현금흐름:
$-156.43M
1주 성능:
-5.39%
1개월 성능:
-5.39%
6개월 성능:
+55.67%
1년 성능:
+11.38%
1일 변동 폭
$16.55
$17.36
1주일 범위
$16.36
$18.52
52주 변동 폭
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
명칭
Crescent Biopharma Inc
전화
617-430-5595
주소
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
17.03 | 467.67M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Piper Sandler | Overweight |
| 2026-01-21 | 개시 | Guggenheim | Buy |
| 2025-08-25 | 개시 | Jefferies | Buy |
| 2025-08-11 | 개시 | H.C. Wainwright | Buy |
| 2025-07-14 | 개시 | Wedbush | Outperform |
| 2025-06-25 | 개시 | Stifel | Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
Enterprise value to EBITDA forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
Price to sales forward of Crescent Biopharma, Inc. – FWB:C68 - TradingView
ETFs Investing in Crescent Biopharma, Inc. Stocks - TradingView
Crescent Biopharma Inc (CBIO) - MSN
Crescent Biopharma files prospectus for $500M mixed shelf - scanx.trade
Form S-3 Crescent Biopharma Inc For: 1 July By Investing.com - Investing.com Canada
Crescent BiopharmaMay Offer And Sell Up To $500 Million Of SecuritiesSEC Filing - TradingView
Crescent Biopharma (NASDAQ: CBIO) files $500M shelf; $200M ATM with Jefferies - Stock Titan
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 2000 Index - marketscreener.com
Crescent Biopharma Company Profile & Introduction - Moomoo
Crescent Biopharma(CBIO) Stock Options Chain | Quotes & News - Moomoo
Crescent Biopharma: Intriguing Developer Of ADC/PD1-VEGF Assets May Not Be Sufficiently Derisked - Seeking Alpha
Crescent Biopharma, Inc.(NasdaqCM:CBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell Microcap Index - marketscreener.com
CBIOCrescent Biopharma Inc Short Interest - Finviz
Crescent Biopharma, Inc. Actuals & Estimates (NASDAQ:CBIO) - TradingView
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
CBIO Forecast — Price Target — Prediction for 2027 - TradingView
Crescent Biopharma awards 65,100 options to 3 new hires - Stock Titan
Stifel Nicolaus Reaffirms Their Buy Rating on Crescent Biopharma (CBIO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma CFO Scalzo sells $20,004 in shares By Investing.com - Investing.com UK
Crescent Biopharma general counsel sells $21,911 in shares - Investing.com UK
Crescent Biopharma CEO Joshua Brumm sells $761k in shares By Investing.com - Investing.com India
Crescent Biopharma CFO Scalzo sells $20,004 in shares - Investing.com UK
Crescent Biopharma general counsel sells $21,911 in shares By Investing.com - Investing.com South Africa
Form 4 Crescent Biopharma Inc For: 23 June - Investing.com UK
Crescent Biopharma CEO Joshua Brumm sells $761k in shares - Investing.com UK
Form 4 Crescent Biopharma Inc For: 23 June By Investing.com - Investing.com Nigeria
CRESCENT BIOPHARMA (CBIO) CMO auto-sells shares to cover RSU taxes - Stock Titan
Crescent Biopharma (CBIO) CFO sells 1,112 shares to cover RSU taxes - Stock Titan
Tax-related insider share sale at Crescent Biopharma (CBIO) under Rule 10b5-1 - Stock Titan
CRESCENT BIOPHARMA (CBIO) CSO’s 1,288-share sale covers RSU tax withholding - Stock Titan
Crescent Biopharma (CBIO) insider sale covers taxes on RSU vesting - Stock Titan
Crescent BioPharma (CBIO) COO tax-related sale of 20,549 shares - Stock Titan
Crescent Biopharma (CBIO) CEO’s pre-planned tax sale covers RSU vesting - Stock Titan
Stifel reiterates Crescent Biopharma stock rating on rival trial data By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Crescent Biopharma stock rating - Investing.com
Cantor Fitzgerald reiterates Crescent Biopharma stock rating By Investing.com - Investing.com Nigeria
Stifel reiterates Crescent Biopharma stock rating on rival trial data - Investing.com
Crescent Biopharma Discloses Executive 10b5-1 Trading Plan Adoptions in Amended Q1 2026 SEC Filing - Minichart
Crescent Biopharma Inc (CBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):